Latest updates, announcements, and stories.
The search for more treatment options in obesity and type 2 diabetes is moving quickly. An oral medicine that acts on both the GLP-1 and GIP pathways could eventually offer another way for some people to receive incretin-based treatment. That possibility is why Viking Therapeutics’ announcement that oral VK2735 has
When people think about type 2 diabetes care, they often think first about glucose or A1c. Those measures matter. But blood pressure can be just as important to long-term heart, brain, and kidney health—and high blood pressure often has no obvious symptoms. That makes a new estimate from an international
Type 2 diabetes can affect—and be affected by—far more than blood glucose. Kidney function, blood pressure, cholesterol, sleep, food access, mental health, stress, inflammation, weight, medications, and cardiovascular disease often intersect. The newer term for this connected landscape is cardiovascular-kidney-metabolic syndrome, or CKM syndrome. A new study uses machine learning
Diabetic kidney disease usually does not announce itself with pain or a dramatic early warning. Changes in urine albumin and kidney filtration can develop quietly, while blood pressure, glucose, cholesterol, medications, food access, and daily routines all influence risk. That is why a recent trial of structured self-management support is
A headline about a new diabetes medicine being “heart safe” can sound like a simple answer: the drug protects the heart. Clinical trials often mean something more precise. A new study of oral orforglipron, marketed as Foundayo for its current U.S. weight-management indication, found that it was noninferior to insulin
A person with type 2 diabetes needs more than a medicine to achieve the best possible health. They need a timely diagnosis, follow-up, food they can access and afford, education that makes sense in their daily life, a safe place and time to move, support for sleep and stress, monitoring,
For many people, the barrier to moving more is not a lack of information. It is time, pain, fatigue, caregiving, shift work, unsafe streets, limited money, disability, or simply the feeling that “exercise” has to look like a gym routine to count. A new study offers an encouraging, limited answer:
Can an eight-hour daily eating window help people with type 1 diabetes? A new randomized trial offers an early, limited signal: a noon-to-8 p.m. schedule was associated with a modest HbA1c improvement versus daily calorie restriction. It did not show that time-restricted eating cures type 1 diabetes, replaces insulin, produces
“May extend lifespan.” “Comparable to metformin.” “Natural alternative.” These phrases can make metformin and berberine sound like interchangeable routes to better health. They are not. They raise different questions, and both require the same evidence standard: What has actually been tested in people, against what comparison, for how long, and
A new long-term study offers an encouraging message for people living with type 2 diabetes: people whose eating patterns scored higher for quality after diagnosis, or improved more over time, had lower observed mortality during follow-up. The study does not show that a particular diet caused people to live longer.
A new study has identified the circulating protein INHBC as a possible link between type 2 diabetes and chronic kidney disease. It is an early research lead, not a treatment, validated blood test, or reason to change medication. The actionable message remains familiar: kidney disease can develop without obvious symptoms,
Needing to urinate more often than usual—especially if it is paired with unusual thirst—can be a sign that blood glucose is elevated. It can also have many other causes, including increased fluid intake, urinary tract infection, medications, prostate conditions, pregnancy, sleep disorders, and other health issues. That is why symptoms
Diabetes can affect many parts of the body, but two complications often travel together: diabetic eye disease and diabetic kidney disease. Both are shaped by long-term metabolic stress and injury to small blood vessels. Researchers have long suspected that they may also share deeper biological pathways. A new PLOS Biology
GLP-1 receptor agonists are often discussed as if they are a single answer to a very complicated condition. In reality, they are one category of prescription medicines that may help selected people with type 2 diabetes, obesity, chronic kidney disease, or cardiovascular risk. The decision to use one depends on
Tirzepatide, sold as Mounjaro for type 2 diabetes in the United States, has become a major part of the public conversation about diabetes and metabolic health. Recent reporting has focused on two related developments: a large real-world study linking tirzepatide with fewer major cardiovascular events than a cardiovascular-neutral comparison medicine,
When people talk about managing type 2 diabetes, the conversation usually turns to food, medications, physical activity, or glucose monitoring. Sleep is often left out—despite the fact that poor sleep can affect energy, mood, appetite, activity, and the ability to follow through on every other part of a care plan.
When people hear that exercise is useful for type 2 diabetes, they may think first about calories, weight loss, or “earning” food. That framing misses much of the biology—and it can make movement feel like a punishment. Muscles are active metabolic organs. When they contract, they use glucose, communicate with
Type 2 diabetes is often discussed through blood glucose, weight, A1c, blood pressure, or cholesterol. Those measures matter. But people living with diabetes are also asking a broader question: What does metabolic health mean for the brain over time? Brain health belongs in the type 2 diabetes conversation That question
Kidney disease is one of the most serious complications associated with type 2 diabetes, yet it can progress quietly. A person may feel well while urine albumin changes, estimated glomerular filtration rate (eGFR) declines, blood pressure rises, or cardiovascular risk increases. That is why early screening and risk assessment matter.
A headline about a “diabetic-friendly” sweetener harming the liver is designed to get attention. It can also leave people with type 2 diabetes wondering whether a piece of sugar-free gum, a product labeled “no sugar,” or fruit is suddenly dangerous. The honest answer is more useful than the alarming one:
GLP-1 medicines are changing more than medication lists. They are changing the market for diabetes support. Employers, health plans, clinicians, and patients are all asking versions of the same question: if a person starts a GLP-1 medicine, what happens around the prescription? Who helps them understand side effects, protect nutrition,
“Food is medicine” is an appealing phrase because it names something many people living with type 2 diabetes already know: food choices are not a side note. They affect energy, glucose patterns, blood pressure, lipids, sleep, and the routines that make treatment sustainable. But the phrase can also become vague.
GLP-1 medicines have become a major part of conversations about weight, blood sugar, and metabolic health. That visibility has created opportunity: some people who once felt shut out of care are now asking better questions about diabetes, obesity, and long-term risk. It has also created a problem. A medication can
Diabetic retinopathy is a diabetes complication that affects the blood vessels of the retina, the light-sensitive tissue at the back of the eye. It can progress without noticeable symptoms in its early stages, which is why regular eye screening matters even when vision seems normal. A recent company announcement described
The human gut contains a large and diverse community of microorganisms. Researchers are increasingly interested in how this ecosystem interacts with digestion, immune signaling, medications, body weight, and metabolic health. One bacterium that appears frequently in this research is Akkermansia muciniphila. Akkermansia lives in the mucus layer of the intestine
Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of fatty liver disease in which excess fat in the liver is accompanied by inflammation and liver-cell injury. Over time, some people develop fibrosis, or scarring, which can progress to cirrhosis and other serious complications. Why MASH matters in a type 2
Source note: This article was prompted by reporting on GLP-1 medicines and aging, plus a commentary on the history of weight-loss culture. The question is not simply “Will it cause weight loss?” GLP-1 receptor agonists have changed the conversation around obesity and type 2 diabetes. These medicines can improve glucose
A more useful conversation than “cure” versus “control” People living with type 2 diabetes deserve more than a conversation limited to “manage this forever” or, at the other extreme, “reverse it quickly.” A better conversation is about remission: a measurable clinical outcome that may be achievable for some people through
A 2026 meta-analysis published in Frontiers in Medicine and supported by a NYU nursing report and a 2026 PubMed-listed review found that Type 2 diabetes and depression share a stronger bidirectional relationship than previously understood — adults with depression have a 60% higher risk of developing Type 2 diabetes, and
New lab research published this month suggests that rhythmic “rest breaks” in pancreatic beta cells help preserve insulin-producing function in Type 2 diabetes, rather than continuously stimulating them. The study, reported by Ohio University researchers and detailed in Science Daily coverage, showed better glucose sensing, improved calcium signaling, and lower
The DiRECT trial — the landmark structured weight-management trial in Type 2 diabetes — just published its 5-year follow-up, showing that remission is possible and durable when weight loss is maintained. At 1 year, 46% of participants in the intervention group were in remission, per the DiRECT primary trial report
Novo Nordisk’s next-generation triple-agonist zenagamtide just hit 89.1% A1c target attainment in phase 2 — one of the highest rates ever reported for a Type 2 diabetes therapy, per the ADA 2026 Scientific Sessions coverage and the Novo Nordisk pipeline announcement. In adults with Type 2 diabetes, the highest dose
A new meta-analysis published in Sports Medicine and reported by News-Medical.net found that combining strength training with aerobic exercise cuts Type 2 diabetes risk more than either modality alone. Across 35 studies and over 90,000 participants, the combination reduced Type 2 diabetes risk by 17–40% depending on dose, with the
A new phase 2b trial of Eli Lilly’s investigational oral GLP-1 elecoglipron showed that up to 89.6% of participants with Type 2 diabetes reached an A1c of 7% or lower, compared with just 24.9% on placebo —and up to 72.3% achieved at least 5% weight loss versus 20.2% on placebo.
Eli Lilly’s retatrutide — the triple-hormone receptor agonist that already made headlines in 2026 for its 2.0% A1c reduction and 16.8% body-weight loss in Type 2 diabetes — just published renal outcomes data in The New England Journal of Medicine. The ORBIT trial evaluated retatrutide in adults with Type 2
The American Diabetes Association’s own consensus definition of type 2 diabetes remission — HbA1c < 6.5% for at least 3 months, off all glucose-lowering medication — just turned five years old, and a growing body of 2026 evidence shows that the vast majority of patients on mainstream diabetes drugs never
Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants
The FDA has approved generic versions of dapagliflozin, a workhorse Type 2 diabetes medication in the SGLT2 inhibitor class, and the coverage has been almost entirely about access. Lower cost. More refills. Fewer prior-authorization fights at the pharmacy counter. For the millions of adults in the US who take a
Eli Lilly’s oral GLP-1, orforglipron, just hit its primary endpoint in the first Phase 3 trial designed to support an FDA submission. The Lilly press release announced results from ACHIEVE-1, published in The New England Journal of Medicine, showing a 1.3%–1.6% A1c reduction and 6.8%–7.9% weight loss in adults with
At the 2026 ADA Scientific Sessions in New Orleans, a team from Leicester launched a three-paper Lancet Series on cardiometabolic multimorbidity — and the agenda tells you exactly where the diabetes conversation is right now. What the Lancet Series Covers The Leicester/NIHR ARC East Midlands team presented three new papers
The most influential diabetes document in America just dropped. The American Diabetes Association’s Standards of Care in Diabetes — published in December 2025 in Diabetes Care (Volume 49, Supplement 1) and now in effect across U.S. endocrinology practices — is the annual clinical playbook that 90%+ of American endocrinologists follow
The FDA just approved the first once-weekly basal insulin for Type 2 diabetes — Novo Nordisk’s Awiqli, greenlit on March 26, 2026 per the FDA Novel Drug Approvals 2026 list, with the U.S. launch expected in the second half of this year. The pitch is simple: one shot a week
The American Diabetes Association’s 2026 Scientific Sessions wrapped last week in New Orleans, and the headlines read like a victory lap. A new once-daily oral GLP-1 called elecoglipron — a small-molecule pill, no injection, no fasting window — sent 89.6% of patients in its phase 2b trial to an A1c
The UK’s National Institute for Health and Care Excellence (NICE) just rewrote the rulebook for Type 2 diabetes. As of this year, GLP-1 receptor agonists and SGLT-2 inhibitors are being prescribed earlier, faster, and to more patients than ever before — and the agency estimates this shift could prevent around
New long-term data from the TRIUMPH-1 extension trial — presented at the American Diabetes Association’s 2026 Scientific Sessions — shows retatrutide drove an average of 30.3% body weight loss a 104 weeks, and 65% of participants dropped below the obesity threshold entirely. That puts a weekly injectable in the same
The race for the first true GLP-1 pill just ended — and it wasn’t even close. Eli Lilly’s once-daily oral GLP-1,orforglipron, just published head-to-head Phase 3 data showing it beat oral semaglutide (the pill form ofOzempic) on both A1c and weight loss. The results dropped this week in The Lancet,
AstraZeneca just reported phase 2 results for a new once-daily GLP-1 pill called elecoglipron. The numbers look great on the surface. The question the press is not asking: does it actually reverse the disease? What the New Study Shows AstraZeneca’s elecoglipron is a once-daily oral GLP-1 receptor agonist — the
The data is now a year old, but it has not been absorbed. In June 2024, the New England Journal of Medicine published the SURMOUNT-OSA trial results: tirzepatide, the GLP-1/GIP drug sold as Mounjaro and Zepbound, reduced sleep apnea severity by roughly 50% in adults with obesity. The 52-week, placebo-controlled
The American Diabetes Association’s 86th Scientific Sessions wrapped last week in New Orleans, and the loudest headline came from Pfizer’s phase 2b VESPER-2 trial of berobenatide, a once-weekly and once-monthly GLP-1 showing a 2.2% A1c reduction and double-digit weight loss in people with Type 2 diabetes — with no plateau
The American Diabetes Association just unveiled the data everyone is talking about, and the headlines are loud. Eli Lilly’s retatrutide, a triple-hormone injection, dropped A1c by up to 2.0% and produced roughly 16.8% body-weight loss in adults with Type 2 diabetes. Pharma is calling it a breakthrough. Wall Street is
Right now, in New Orleans, 12,000 of the world’s top diabetes researchers are gathered at the ADA 2026 Scientific Sessions. The headlines pouring out of that meeting this week are dominated by one thing: GLP-1 drugs got bigger. The 25 mg dose of the latest incretin therapies produced larger A1c